AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. Table of Contents. ERIC is an online library of education research and information, sponsored by the Institute of Education Sciences (IES) of the U.S. Department of Education. Emergency Medical Services Intervals and Survival in Trauma: Assessment of the “Golden Hour” in a North American Prospective Cohort. This paper examines the literature on computer games and serious games in regard to the potential positive impacts of gaming on users aged 14 years or above, es. This paper includes a review of the different computer tools that can be used to analyse the integration of renewable energy. Initially 68 tools were considered. MMTV/ c-neu transgenic mice express an activated rat c-neu oncogene ( Erbb2) under the direction of the the mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter. These mice may be useful in. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart. Preamble 2. 07. 2Introduction 2. Methodology and Evidence Review 2. Organization of the Writing Committee 2. Document Review and Approval 2. Scope of the Guideline 2. Clinical Characteristics and Evaluation of AF 2. AF Classification 2. Mechanisms of AF and Pathophysiology 2. Risk Factors and Associated Heart Disease 2. Clinical Evaluation: Recommendation 2. Connolly Database Systems Pdf DownloadThromboembolic Risk and Treatment 2. Risk- Based Antithrombotic Therapy: Recommendations 2. Risk Stratification Schemes (CHADS2 and CHA2. DS2- VASc) 2. 07. Considerations in Selecting Anticoagulants 2. Cardiac Surgery—Left Atrial Appendage Occlusion/Excision: Recommendation 2. Rate Control: Recommendations 2. Rhythm Control: Recommendations 2. Prevention of Thromboembolism 2. Direct- Current Cardioversion 2. Pharmacological Cardioversion 2. Antiarrhythmic Drugs to Maintain Sinus Rhythm 2. Upstream Therapy 2. AF Catheter Ablation to Maintain Sinus Rhythm 2. Surgical Maze Procedures 2. Specific Patient Groups and AF: Recommendations 2. Hypertrophic Cardiomyopathy 2. AF Complicating Acute Coronary Syndromes 2. Hyperthyroidism 2. Pulmonary Disease 2. Wolff- Parkinson- White and Pre- Excitation Syndromes 2. Heart Failure 2. 08. Familial (Genetic) AF 2. Postoperative Cardiac and Thoracic Surgery 2. Evidence Gaps and Future Research Directions 2. References 2. 09. Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2. Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant) 2. Appendix 3. Initial Clinical Evaluation in Patients With AF 2. Preamble. The medical profession should play a central role in evaluating the evidence related to drugs, devices, and procedures for the detection, management, and prevention of disease. When properly applied, expert analysis of available data on the benefits and risks of these therapies and procedures can improve the quality of care, optimize patient outcomes, and favorably affect costs by focusing resources on the most effective strategies. An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist clinicians in selecting the best management strategy for an individual patient. Moreover, clinical practice guidelines can provide a foundation for other applications, such as performance measures, appropriate use criteria, and both quality improvement and clinical decision support tools. The American College of Cardiology (ACC) and the American Heart Association (AHA) have jointly engaged in the production of guidelines in the area of cardiovascular disease since 1. The ACC/AHA Task Force on Practice Guidelines (Task Force), whose charge is to develop, update, or revise practice guidelines for cardiovascular diseases and procedures, directs this effort. Writing committees are charged with the task of performing an assessment of the evidence and acting as an independent group of authors to develop, update, or revise written recommendations for clinical practice. Experts in the subject under consideration are selected from both organizations to examine subject- specific data and write guidelines. Writing committees are specifically charged to perform a literature review; weigh the strength of evidence for or against particular tests, treatments, or procedures; and include estimates of expected health outcomes where such data exist. Patient- specific modifiers, comorbidities, and issues of patient preference that may influence the choice of tests or therapies are considered, as well as frequency of follow- up and cost- effectiveness. When available, information from studies on cost is considered; however, review of data on efficacy and outcomes constitutes the primary basis for preparing recommendations in this guideline. In analyzing the data, and developing recommendations and supporting text, the writing committee uses evidence- based methodologies developed by the Task Force. The Classification of Recommendation (COR) is an estimate of the size of the treatment effect, with consideration given to risks versus benefits, as well as evidence and/or agreement that a given treatment or procedure is or is not useful/effective or in some situations may cause harm; this is defined in Table 1. The Level of Evidence (LOE) is an estimate of the certainty or precision of the treatment effect. The writing committee reviews and ranks evidence supporting each recommendation, with the weight of evidence ranked as LOE A, B, or C, according to specific definitions that are included in Table 1. Studies are identified as observational, retrospective, prospective, or randomized, as appropriate. For certain conditions for which inadequate data are available, recommendations are based on expert consensus and clinical experience and are ranked as LOE C. When recommendations at LOE C are supported by historical clinical data, appropriate references (including clinical reviews) are cited if available. Table 1. Applying Classification of Recommendations and Level of Evidence. For issues with sparse available data, a survey of current practice among the clinician members of the writing committee is the basis for LOE C recommendations and no references are cited. The schema for COR and LOE is summarized in Table 1, which also provides suggested phrases for writing recommendations within each COR. A new addition to this methodology is the separation of the Class III recommendations to delineate whether the recommendation is determined to be of “no benefit” or is associated with “harm” to the patient. In addition, in view of the increasing number of comparative effectiveness studies, comparator verbs and suggested phrases for writing recommendations for the comparative effectiveness of one treatment or strategy versus another are included for COR I and IIa, LOE A or B only. In view of the advances in medical therapy across the spectrum of cardiovascular diseases, the Task Force has designated the term guideline- directed medical therapy to represent optimal medical therapy as defined by ACC/AHA guideline (primarily Class I)–recommended therapies. This new term, guideline- directed medical therapy, is used herein and throughout subsequent guidelines. Therapies not available in the United States are discussed in the text without a specific COR. For studies performed in large numbers of subjects outside North America, each writing committee reviews the potential impact of different practice patterns and patient populations on the treatment effect and relevance to the ACC/AHA target population to determine whether the findings should inform a specific recommendation. The ACC/AHA practice guidelines are intended to assist clinicians in clinical decision making by describing a range of generally acceptable approaches to the diagnosis, management, and prevention of specific diseases or conditions. The guidelines attempt to define practices that meet the needs of most patients in most circumstances. The ultimate judgment about care of a particular patient must be made by the clinician and patient in light of all the circumstances presented by that patient. As a result, situations may arise in which deviations from these guidelines may be appropriate. Clinical decision making should involve consideration of the quality and availability of expertise in the area where care is provided. When these guidelines are used as the basis for regulatory or payer decisions, the goal should be improvement in quality of care. The Task Force recognizes that situations arise in which additional data are needed to inform patient care more effectively; these areas are identified within each respective guideline when appropriate. Prescribed courses of treatment in accordance with these recommendations are effective only if followed. Because lack of patient understanding and adherence may adversely affect outcomes, clinicians should make every effort to engage the patient’s active participation in prescribed medical regimens and lifestyles. In addition, patients should be informed of the risks, benefits, and alternatives to a particular treatment and should be involved in shared decision making whenever feasible, particularly for COR IIa and IIb, for which the benefit- to- risk ratio may be lower. The Task Force makes every effort to avoid actual, potential, or perceived conflicts of interest that may arise as a result of relationships with industry and other entities (RWI) among the members of the writing committee. All writing committee members and peer reviewers of the guideline are required to disclose all current healthcare- related relationships, including those existing 1. In December 2. 00. ACC and AHA implemented a new RWI policy that requires the writing committee chair plus a minimum of 5. RWI (Appendix 1 includes the ACC/AHA definition of relevance). The Task Force and all writing committee members review their respective RWI disclosures during each conference call and/or meeting of the writing committee, and members provide updates to their RWI as changes occur. All guideline recommendations require a confidential vote by the writing committee and require approval by a consensus of the voting members. Members may not draft or vote on any recommendations pertaining to their RWI. Members who recused themselves from voting are indicated in the list of writing committee members, and specific section recusals are noted in Appendix 1. Authors’ and peer reviewers’ RWI pertinent to this guideline are disclosed in Appendixes 1 and 2. In addition, to ensure complete transparency, writing committee members’ comprehensive disclosure information—including RWI not pertinent to this document—is available as an online supplement. Comprehensive disclosure information for the Task Force is also available online at http: //www. ACC/About- ACC/Who- We- Are/Leadership/Guidelines- and- Documents- Task- Forces.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2016
Categories |